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Simple Summary: It is largely unknown how frequently cancer patients seen in routine care show
ventricular arrhythmias during 24-h electrocardiograms. We have found that non–sustained ventricu-
lar tachycardia episodes of ≥3 and ≥4 beats duration were more frequent in cancer patients than con-
trols. Non–sustained ventricular tachycardia with ≥4 beats and ≥20 premature ventricular contrac-
tions/day seen in routine 24-h electrocardiograms of patients with cancer carry prognostic relevance.
Abstract: Aims: It is largely unknown whether cancer patients seen in routine care show ventricular
arrhythmias in 24 h electrocardiograms (ECGs), and whether when they are detected they carry
prognostic relevance. Methods and Results: We included 261 consecutive cancer patients that were
referred to the department of cardiology for 24 h ECG examination and 35 healthy controls of similar
age and sex in the analysis. To reduce selection bias, cancer patients with known left ventricular ejec-
tion fraction <45% were not included in the analysis. Non–sustained ventricular tachycardia (NSVT)
episodes of either ≥3 and ≥4 beats duration were more frequent in cancer patients than controls
(17% vs. 0%, p = 0.0008; 10% vs. 0%, p = 0.016). Premature ventricular contractions (PVCs)/24 h were
not more frequent in cancer patients compared to controls (median (IQR), 26 (2–360) vs. 9 (1–43),
p = 0.06; ≥20 PVCs 53% vs. 37%, p = 0.07). During follow-up, (up to 7.2 years, median 15 months)
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of the cancer patients, 158 (61%) died (1-/3-/5-year mortality rates: 45% [95% CI 39–51%], 66%
[95% CI 59–73%], 73% [95% CI 64–82%]). Both non-sustained ventricular tachycardia of ≥4 beats
and ≥20 PVCs/24 h independently predicted mortality in univariate and multivariate survival
analyses, adjusted for all other univariate predictors of mortality as well as relevant clinical factors,
including cancer stage and type, performance status (ECOG), prior potentially cardiotoxic anti-cancer
drug therapy, coronary artery disease, potassium concentration, and haemoglobin (multivariate
adjusted hazard ratios: NSVT ≥4 beats [HR 1.76, p = 0.022], ≥20 PVCs/24 h [HR 1.63, p < 0.0064]).
Conclusions: NSVT ≥4 beats and ≥20 PVCs/day seen in routine 24 h ECGs of patients with cancer
carry prognostic relevance.
Keywords: ventricular arrhythmia; non-sustained ventricular tachycardia; ventricular premature
contractions; cancer; survival
1. Introduction
In retrospective cohort studies, cardiovascular (CV) death as cause of death is reported
in about 10–30% of patients with cancer [1,2]. There are many anti–cancer therapies such as
anthracylines, trastuzumab, and cyclophosphamide that are known to cause cardiotoxicity
in up to half of cancer patients, depending on the cancer type and drug dosage [3]. In order
to initiate preventive measures against cardiotoxicity in cancer patients there is an urgent
need to find reliable biomarkers. With regards to blood biomarkers, troponin is helpful in
monitoring cancer patients during anti–cancer therapy and in the identification of patients
with an increased risk of cardiotoxicity [4]. Previous research has shown that the resting
heart rate in cancer patients without significant cardiovascular disease is a significant and
independent predictor of all-cause mortality in multivariate survival analysis [5].
We hypothesized that cancer patients in routine care experience metabolic changes—
caused by anti-cancer therapy and the overall catabolic state of the cancer disease—that
could result in significant ventricular arrhythmias associated with worse survival. Since
ventricular arrhythmias are frequently seen in patients with reduced left ventricular ejection
fraction (LVEF) [6], we excluded patients with known LVEF <45%. We know of no other
study that has examined the overall occurrence of ventricular arrhythmia in cancer patients
in any real world clinical setting. In this retrospective, observational cohort study we
examined the presence of spontaneous non-sustained ventricular tachycardia (NSVT), the
length of the NSVT runs, and the number of premature ventricular contractions (PVCs)
detected during routine 24-h electrocardiogram (24 h ECG) recordings, as well as their
prognostic relevance in routinely treated cancer patients.
2. Methods
2.1. Study Population
Between 1 February 2012, and 31 May 2018, the total number of adult (age ≥ 18 years)
cancer patients cared for on the oncology wards of Campus CBF of the Charité was 39,699.
Of these patients, we reviewed the medical records of all cancer patients with histologically
confirmed cancer who had undergone a 24-h ECG recording (n = 277). These 277 24-h ECG
recordings represent 1.4% of all 19,810 24-h ECG recorded in the Cardiology Department
in the time frame of interest. None of these 277 cancer patients had a repeat 24-h ECG in
the study period. Patients with known left ventricular ejection fraction (LVEF) <45% were
excluded (n = 16)—leaving 261 patients with a cancer diagnosis and an available 24-h ECG
for analyses, which represents a subgroup of 0.7% (261/39,699) of all cancer patients cared
for in that time period in Campus CBF of Charité (median time between 24-h ECG and
echocardiogram 1 day [interquartile range 0–10 days]).
In the patients of interest, we reviewed the medical records for cancer stage and entity,
clinical and laboratory baseline characteristics, ECOG (Eastern Cooperative Oncology
Group) performance status [7], echocardiograms, and secondary diagnoses, closest to the
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24-h ECGG recording. We followed all cancer patients for all-cause mortality through
3 July 2019. Additionally, we included a retrospective cohort of 35 generally healthy
controls that received a 24-h ECG, echocardiogram, and routine blood chemistry as part of
a preventive examination in 2018. All control subjects had similar age and sex compared to
the cancer patients, and were free of cancer and significant cardiovascular disease, other
than controlled arterial hypertension.
All cancer patients were followed-up for all-cause mortality by monitoring of the
electronic database of the Charité. The study plan was approved by the Charité ethics
committee and complies with the Declaration of Helsinki.
2.2. 24-h Electrocardiograms
A standard 24-h ECG was performed in all patients. CardioDay Version 2.4.5 (Getemed
AG, Teltow, Germany) was used for analysis of 24-h ECGs and the results were verified by
AA, MSA, and WH. We recorded total number of premature atrial contractions and pre-
mature ventricular contractions (PVCs), presence and length of non-sustained ventricular
tachycardia (NSVT), and average 24-h heart rate (in beats per minute, bpm). Following
the recommendations of the WHO and EHRA/HRS/APHRS [8,9], NSVT was defined as
≥3 consecutive heartbeats exceeding a heart rate of 100 beats per minute and originating
from the ventricular heart chamber.
2.3. Statistical Analyses
Data are presented as either mean ± standard deviation (SD) or median with interquar-
tile range (IQR). The Kolmogorov–Smirnov test was used to assess normal distribution.
We used unpaired Student’s t-test to compare two normally distributed groups and Mann–
Whitney U test for non-normally distributed data. The contingency tables were preferably
analysed with Chi-squared test. For 2 × 2 tables with at least one cell assignment smaller
than five, we used the Barnard’s test [10–12]. For survival analyses, we used the Cox-
proportional hazard survival analyses (log-rank test). Results are given as hazard ratios
(HRs) with 95% confidence intervals (95% CI) for risk factors. Kaplan Meier curves were
generated for illustration purposes. Since this study was designed to identify patterns, it
was unnecessary to test for multiplicity and the significance tests are descriptive [13,14].
For statistical analyses, we used “R 1.1.463”, “Stat View 5.0 software” (SAS Institute, Inc.,
Cary, NC, USA), and “IBM SPSS Version 25.0” (IBM, Armonk, NY, USA). We considered a
p-value < 0.05 as statistically significant in all analysis.
3. Results
3.1. Study Population
We included 261 consecutive cancer patients (129 with solid cancers and 132 patients
with haematological malignancies, Table S1) that were referred to the department of
cardiology for 24-h ECG examination, and 35 healthy controls of similar age and sex (all
Caucasians). Baseline characteristics are shown in Table 1 and baseline medication in
Table S2. In 181 cancer patients and all 35 controls, LVEF was assessed. LVEF was similar
between cancer patients and controls (65 ± 7 vs. 64 ± 7, p = 0.81). Follow-up of patients
ended on July 3, 2019, after a median of 15 months (maximum 7.2 years). 188 patients
(72%) had an advanced cancer stage (≥III). 158 cancer patients (61%) died during follow-up
(1-/3-/5-year mortality: 45% [95% CI 39–51%], 66% [59–73%], 73% [64–82%]).
199 patients (76%) had previously received some kind of anti-cancer drug therapy
before and 162 patients (62%) some kind of potentially cardiotoxic anti-cancer drugs [3].
Haemoglobin, sodium, and potassium concertation were lower in cancer patients vs.
controls (median time between 24-h ECG and blood sample 1 day [interquartile range
0–2 days]). Since only generally healthy controls were included, secondary diagnoses and
different drug treatments were more frequently observed in cancer patients than in the
controls (Table 1, Tables S2 and S3).
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Table 1. Baseline characteristics.
Variable Healthy Controls(n = 35)
Cancer Patients




(n = 103) p-Value
Clinical characteristics







Female sex, n (%) 19 (54) 132 (51) 0.68 76 (48) 56 (54) 0.32
BMI (kg/m2) 26 ± 4 24 ± 5 0.28 25 ± 5 26 ± 5 0.049
Cancer stage ≥III, n (%) – 188 (72) – 123 (78) 65 (63) 0.0095
Cancer type: solid, n (%) – 129 (49) – 93 (59) 36 (35) 0.0002
ECOG performance status
≥2, n (%) – 111 (43) – 75 (47) 36 (35) 0.046
Prior potentially cardiotoxic
anti-cancer drugs, n (%) – 162 (62) – 104 (66) 58 (56) 0.12
Left ventricular
ejection fraction (%) 64 ± 7 65 ± 7 (n = 181) 0.81 64 ± 8 (n = 100) 65 ± 7 (n = 81) 0.27
Laboratory parameters
Haemoglobin (g/dL) 14.2 ± 1.3 10.8 ± 2.0 <0.0001 10.6 ± 1.9 11.1 ± 2.1 0.040
Leucocytes (/nL) 6.6 (5.5–7.6) 6.5 (4.3-9.6) 0.99 6.9 (4.4–9.9) 6.1 (4.3–9.2) 0.40
Platelets (/nL) 227 ± 46 225 ± 166 0.97 231 ± 195 217 ± 108 0.48
Sodium (mmol/L) 141 ± 2 139 ± 4 0.0002 138 ± 4 140 ± 3 0.0027
Potassium (mmol/L) 4.2 ± 0.4 3.9 ± 0.5 0.0004 3.9 ± 0.5 3.9 ± 0.5 0.91
Creatinine (mg/dL) 0.87 ± 0.19 1.00 ± 0.59 0.22 1.03 ± 0.68 0.94 ± 0.40 0.23




(n = 70) 0.34
Secondary diagnoses
Arterial hypertension, n (%) 7 (20) 132 (51) 0.0007 79 (50) 53 (51) 0.82
Coronary artery disease, (%) 0 34 (13) 0.0040 22 (14) 12 (12) 0.59
Atrial fibrillation, n (%) 0 14 (5) 0.08 8 (5) 6 (6) 0.79
Previous myocardial infarction,
n (%) 0 20 (8) 0.033 13 (8) 7 (7) 0.67
Diabetes mellitus type 2, n (%) 0 50 (19) 0.0003 31 (20) 19 (18) 0.81
Chronic kidney disease, n (%) 0 41 (16) 0.0014 28 (18) 13 (13) 0.27
Previous stroke, n (%) 0 27 (10) 0.011 17 (11) 10 (10) 0.79
Current use of antibiotics, n (%) 0 45 (17) 0.0007 33 (21) 12 (12) 0.054
24 h-ECG
Average 24 h heart rate (bpm) 70 ± 9 78 ± 14 0.0007 79 ± 16 77 ± 11 0.41
No. of premature atrial
contractions/24 h 82 (27–302) 195 (27–1167) 0.22 227 (32–1226) 146 (24–761) 0.20
No. of premature ventricular
contractions/24 h 9 (1–43) 26 (2–360) 0.06 54 (4–467) 12 (1–280) 0.013
≥20 Premature ventricular
contractions/24 h, n (%) 13 (37) 139 (53) 0.07 95 (60) 44 (43) 0.0059
≥50 Premature ventricular
contractions/24 h, n (%) 8 (23) 117 (45) 0.013 80 (51) 37 (36) 0.020
NSVT with ≥3 beats & ≥100 bpm,
n (%) 0 44 (17) 0.0008 31 (20) 13 (13) 0.14
NSVT with ≥4 beats & ≥100 bpm,
n (%) 0 25 (10) 0.016 21 (13) 4 (4) 0.0066
Values are means ± SD, or n (%), or for abnormal distributed data median and Interquartile Range (IQR). Significant p-values (p < 0.05) are
bold. 24 h, 24 hour; bpm, beats per minute; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; GOT, glutamic oxaloacetic
transaminase; No. of premature atrial contractions/24 h, total number of premature atrial contractions recorded per 24 h; No. of premature
ventricular contractions/24 h, total number of premature ventricular contractions recorded per 24 h; NSVT, non-sustained ventricular
tachycardia; mmol/L, millimoles per litre; g/dL, grams per decilitre; kg/m2, kilogram per square meter; U/L, Units per litre;/nL, per
nanolitre; ms, milliseconds.
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3.2. 24-h Electrocardiograms
The most frequent reasons for recording a 24 h ECG were syncope or falls, suspected
atrial fibrillation or atrial tachycardia, screening for CV disease, or clinical study participation
(each ~20%, Figure 1). Analysis of all 24-h ECGs showed that non–sustained ventricular
tachycardia (NSVT) with ≥3 and ≥4 beats were more frequent in cancer patients than in
the controls (17% vs. 0%, p = 0.0008; 10% vs. 0%, p = 0.016)—Table 1, Figure 2A). Premature
atrial contractions/24 h was not significantly increased in cancer patients vs. the controls.
Premature ventricular contractions (PVCs)/24 h showed a tendency towards higher frequency
in cancer patients (median (IQR), 26 (2–360) vs. 9 (1–43), p = 0.06; ≥20 PVCs 53% vs. 37%,
p = 0.07; ≥50 PVCs 23% vs. 45%, p = 0.013 (Figure 2B). Average 24-h heart rate was higher
in cancer patients. In cancer patients with NSVT ≥4 beats and ≥20 PVCs/24 h, LVEF was
similar to patients without these arrhythmias (Tables S4 and S5).
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gastrointestinal; bpm, beats per minute, * p < 0.05, ** p < 0.01, vs. healthy controls; (B) Proportion of subjects with ≥20
PVCs & ≥50 PVC/24 h. PVCs, premature ventricular contractions; GI, gastrointestinal; bpm, beats per minute, * p < 0.05,
** p < 0.01, *** p < 0.001, vs. healthy controls.
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3.3. Comparing Patients with and without Ventricular Arrhythmias
Subgroup analyses showed that patients with NSVT ≥4 beats more frequently had
coronary artery disease, more often used angiotensin-converting enzyme inhibitors, had
higher average 24 h heart rate, and more PVCs/24 h (Table S4). Patients with ≥20 PVCs
were older, had higher average 24 h heart rate, had more premature atrial contractions/24 h
and NSVT with ≥4 beats, were more often female, had more frequently arterial hyperten-
sion, coronary artery disease, and previous myocardial infarction, and more often used
angiotensin-converting enzyme inhibitor (Table S5).
3.4. Comparing Patients with and without Death during Follow-Up
We compared patients with vs. without a fatal event during follow-up (Table 1).
Patients with a fatal event had higher age, more frequently advanced cancer stage, and
solid cancers, and lower body mass index (BMI), haemoglobin, and sodium levels. NSVT
≥4 beats were more frequent in patients with fatal event (13% vs. 4%, p = 0.0066). Pa-
tients with fatal events had a higher number of PVCs/24 h (median (IQR), 54 (4–467) vs.
12 (1–280), p = 0.013) and more frequently ≥20 PVCs/24 h (60% vs. 43%, p = 0.0059).
3.5. Survival Analyses
Univariate and multivariate Cox-proportional hazard analyses in all cancer patients
showed that NSVT ≥4 beats and ≥20 PVCs/24 h were associated with higher all-cause
mortality (Table 2). Of note, NSVT ≥3 beats was not a significant predictor of mortality
(univariate HR 1.22, 0.82–1.81, p = 0.32). For both risk factors (i.e., NSVT ≥4 beats and ≥20
PVCs/24 h), we conducted two multivariate models. In the first model, we included all
univariate predictors of death and in the second additionally all other clinically relevant
variables. Univariate Cox-proportional hazard analyses showed that PVCs/24 h in con-
tinuous analyses were no significant predictor of mortality. ROC analyses regarding the
number of PVCs per day in cancer patients identified ≥20 PVCs as the best nominal pre-
dictor of mortality (area under the curve 59.1%, 95% CI 52.0%-66.3%), which was therefore
used for the multivariate survival analysis described above. ROC analyses including the
highest number of connected PVCs with a heart rate ≥100 bpm identified NSVTs with
≥4 beats as the best nominal predictor of mortality (area under the curve 57.4%, 95% CI
50.4–64.4%), which was therefore used for the multivariate survival analysis described
above. For illustrative purposes, we constructed Kaplan-Maier curves showing the survival
benefit of patients without NSVT ≥4 beats or ≥20 PVCs (Figure 3A,B).
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Table 2. Univariate and Multivariate survival analyses in cancer patients (n = 261).
Variable Univariate Model
HR 95% CI χ2 p-Value
Significant and Clinically Relevant Variables
NSVT ≥4 beats & ≥100 bpm (yes vs. no) 1.66 1.04–2.63 4.6 0.033
≥20 Premature ventricular contractions/24 h (yes vs. no) 1.67 1.21–2.30 9.9 0.0017
Age (per 1 year) 1.01 1.001–1.03 4.3 0.039
BMI (per 1 kg/m2) 0.95 0.91–0.98 8.1 0.0043
Cancer stage (≥III vs. I/II) 1.66 1.14–2.42 7.0 0.0082
Cancer type (solid vs. haematologic) 2.09 1.52–2.87 20.3 <0.0001
ECOG performance status (≥2 vs. 0/1) 1.58 1.15–2.17 8.2 0.0043
Haemoglobin (per 1 g/dL) 0.91 0.84–0.99 5.3 0.021
Sodium (per 1 mmol/L) 0.94 0.90–0.98 10.4 0.0013
Opioids (yes vs. no) 1.67 1.13–2.47 6.7 0.0097
Antidepressants (yes vs. no) 1.85 1.14–2.99 6.2 0.013
Prior potentially cardiotoxic anti-cancer drugs (yes vs. no) 1.41 1.02–1.96 4.2 0.039
Sex (female vs. male) 0.80 0.59–1.10 1.9 0.17
Potassium (per 1 mmol/L) 1.07 0.78–1.48 0.2 0.66
Current use of antibiotics (yes vs. no) 1.29 0.88–1.90 1.7 0.19
Coronary artery disease (yes vs. no) 0.99 0.63–1.56 0.001 0.98
Variable Multivariate Model 1 Multivariate Model 2
HR 95% CI χ2 p-Value HR 95% CI χ2 p-Value
Multivariate Survival Analyses in Cancer Patients with NSVT ≥4 beats & ≥100 bpm
NSVT ≥4 beats & ≥100 bpm (yes vs. no) 1.82 1.13–2.94 6.0 0.015 1.76 1.09–2.84 5.3 0.022
Age (per 1 year) 1.02 1.01–1.04 8.4 0.0038 1.02 1.01–1.04 8.2 0.0041
Sodium (per 1 mmol/L) 0.96 0.92–1.002 3.5 0.061 0.96 0.92–1.003 3.4 0.07
Haemoglobin (per 1 g/dL) 0.92 0.84–1.0003 3.8 0.051 0.92 0.84–1.004 3.5 0.06
BMI (per 1 kg/m2) 0.96 0.93–0.996 4.7 0.031 0.96 0.92–0.998 4.2 0.041
Opioids (yes vs. no) 1.33 0.88–2.03 1.8 0.18 1.33 0.87–2.04 1.7 0.19
Cancers 2021, 13, 2303 10 of 15
Table 2. Cont.
Antidepressants (yes vs. no) 1.50 0.91–2.47 2.6 0.11 1.60 0.97–2.64 3.4 0.07
Cancer stage (≥III vs. I/II) 1.50 1.01–2.21 4.1 0.043 1.52 1.03–2.24 4.4 0.037
Cancer type (solid vs. haematologic) 2.46 1.75–3.46 26.9 <0.0001 2.54 1.80–3.59 27.7 <0.0001
ECOG performance status (≥2 vs. 0/1) 1.23 0.87–1.73 1.4 0.24 1.40 0.97–2.01 3.3 0.07
Prior potentially cardiotoxic anti-cancer drugs (yes vs. no) 1.68 1.18–2.40 8.2 0.0041 1.70 1.19–2.43 8.4 0.0037
Sex (female vs. male) 0.68 0.48–0.95 5.1 0.024
Potassium (per 1 mmol/L) 1.15 0.83–1.59 0.7 0.40
Current use of antibiotics (yes vs. no) 1.33 0.88–1.99 1.8 0.18
Coronary artery disease (yes vs. no) 1.02 0.62–1.67 0.004 0.95
Multivariate Survival Analyses in Cancer Patients with ≥20 Premature Ventricular Contractions
≥20 Premature ventricular contractions/24 h (yes vs. no) 1.71 1.22–2.40 9.7 0.0019 1.63 1.15–2.31 7.4 0.0064
Age (per 1 year) 1.01 0.9991–1.03 3.4 0.07 1.02 0.99995–1.03 3.8 0.05
Sodium (per 1 mmol/L) 0.97 0.92–1.008 2.6 0.11 0.96 0.92–1.008 2.6 0.11
Haemoglobin (per 1 g/dL) 0.91 0.83–0.989 4.9 0.027 0.91 0.83–0.991 4.7 0.031
BMI (per 1 kg/m2) 0.96 0.92–0.993 5.3 0.021 0.96 0.92–0.996 4.6 0.032
Opioids (yes vs. no) 1.21 0.80–1.84 0.84 0.36 1.22 0.79–1.86 0.8 0.37
Antidepressants (yes vs. no) 1.60 0.97–2.64 3.5 0.06 1.67 1.01–2.75 4.1 0.044
Cancer stage (≥III vs. I/II) 1.64 1.11–2.42 6.1 0.014 1.63 1.10–2.41 6.0 0.014
Cancer type (solid vs. haematologic) 2.44 1.74–3.43 26.5 <0.0001 2.49 1.77–3.52 27.0 <0.0001
ECOG performance status (≥2 vs. 0/1) 1.30 0.92–1.84 2.3 0.13 1.47 1.02–2.11 4.4 0.037
Prior potentially cardiotoxic anti-cancer drugs (yes vs. no) 1.53 1.07–2.17 5.5 0.019 1.54 1.08–2.20 5.6 0.018
Sex (female vs. male) 0.69 0.49–0.97 4.6 0.03
Potassium (per 1 mmol/L) 1.14 0.83–1.57 0.6 0.42
Current use of antibiotics (yes vs. no) 1.24 0.82–1.86 1.0 0.31
Coronary artery disease (yes vs. no) 0.91 0.55–1.50 0.1 0.71
Hazard ratios are presented for continuously or binomially distributed variables. Model 1 includes all significant univariate predictors of mortality. Model 2 includes all significant univariate predictors of
mortality and other clinically important variables. Significant p-values (p < 0.05) are bold. 24 h, 24 hour; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; bpm, beats per minute; CI,
Confidence interval. HR, hazard ratio; NSVT, non-sustained ventricular tachycardia; mmol/L, millimoles per litre; g/dL, grams per decilitre; kg/m2, kilogram per square meter; U/L.
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4. Discussion
This retrospective study shows that spontaneous NSVTs are seen more frequently in
cancer patients in a clinical routine setting compared to what is found in healthy control
subjects of similar age and sex. The number of PVCs/day also showed a tendency towards
a higher incidence in cancer patients. The presence of NSVT of ≥4 beats and ≥20 PVCs/day
independently carried relevant prognostic information.
It is important to note that this was a retrospective investigation, and we did not
control the reasons for which these cancer patients underwent 24-h ECG recording, other
than excluding patients with an LVEF <45%. There may have been selection biases with
these cancer patients more likely having other CV risks than in an unselected cohort of
cancer patients. It is of note, therefore, that we have recently published the results of a
prospective study in 120 unselected patients with solid cancers without severe CV disease
(diagnoses: colon, lung, or pancreatic cancer) who were followed for up to 12.5 years for
survival [15]. In that study we found that both NSVTs (defined as ≥3 beats & heart rate
≥100 bpm), were present in 8% of cancer patients and the absolute number of PVCs per day
predicted mortality (multivariate adjusted hazard ratio for NSVT [HR 2.44, p < 0.05] and
PVCs [per 100, HR 1.021, p < 0.05]). The best cut-off for mortality prediction with respect
to PVCs in patients with pancreatic and colorectal cancer was ≥50 PVCs/day (HR 2.30,
p < 0.01), which was present in 26% of pancreatic and 18% of colorectal cancer patients.
In comparison, all 24-h ECGs in the current retrospective cohort were commissioned
by a clinician and therefore were highly preselected. Only 0.7% (277/39,699) of patients
with cancer that were treated in our hospital during the investigational period between
2012–2018 received a 24-h ECG and no patient received more than one 24-h ECG in this
time period. Therefore, even though we excluded patients with known LVEF <45%, the
current cohort had a much higher pre-test probability of finding ventricular arrhythmias.
Consequently, NSVTs during 24-h ECGs in patients with cancer were observed more
often in this retrospective cohort (i.e., in 17% of cancer patients), representing a 125%
(16.86%/7.50%) higher incidence than in the prospectively studied cohort of cancer patients.
Regarding the number of PVCs per day (here a median of 26), this represents a 550% higher
value than in the prospective cohort of cancer patients [15]. It appears that only prospective
studies can give realistic estimates for the presence of arrhythmias in cancer patients.
Retrospective studies give values that are false high.
Still, both studies found an increased incidence of NSVTs in cancer patients compared
to healthy controls (both p < 0.05) [15]. In healthy people in general, NSVTs are only
rarely seen—an analysis from 22 phase 1 studies with a total of 1273 healthy volunteers
that received 24-h ECGs found that NSVTs occurred in only 0.7% of patients (n = 9/1273,
0.7%) [16]—showing that both the 8% and 17% incidence of NSVTs in cancer patients in
our reports are considerably higher than in healthy people. On the other hand, the number
of premature atrial contractions/day was not significantly different here (median 195 vs.
82, p = 0.22). To better understand these issues, further prospective and mechanistic studies
are needed to better understand the underlying pathomechanisms.
In this retrospective study we found that the best cut-offs for survival prediction
with regards to NSVT was slightly higher (≥4 beats) than in the prospective cohort
(≥3 beats). The current results were multivariate adjusted for many confounders including
age, haemoglobin and potassium levels, BMI, cancer type and stage, ECOG, prior poten-
tially cardiotoxic anti-cancer drugs, and coronary artery disease. NSVTs with ≥3 beats
did not predict mortality in this cohort. The best cut-off for mortality prediction regarding
PVCs/day was low in both cohorts: in the retrospective cohort at ≥20 PVCs/day and
in the prospective cohort at ≥50 PVCs/day [15]. In both studies, this represented circa
0.5 PVCs per hour or circa 0.02–0.04% of all heart beats in one day.
Our results show, that in general 24-h ECGs should be performed more often in cancer
patients and that they can identify those cancer patients with an increased risk of death.
We think, especially those patients with palpitations, syncopal events, or multiple PVCs
during resting ECG analysis, should be considered for referral for 24-h ECG recordings.
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Only if 24-h ECGs in cancer patients are performed more often in clinical studies and
daily clinical routine can this lead to a better understanding of the underlying mechanisms.
According to the current ESC guideline on ventricular arrhythmias “in hemodynamically
relevant NSVT, amiodarone (300 mg i.v. bolus) should be considered” [17]. Of course, these
guidelines were not written with cancer patients in mind and should be tested in cancer
patients. Future studies should also evaluate long-term treatments for cancer patients that
have shown NSVTs and/or increased number of PVCs during 24-h ECGs.
Considering the limitations of this study, first of all, this study was of a retrospective
nature; many different cancer entities were included in the analysis. In total, 35 different
cancer entities were included (129 patients with solid cancers and 132 with haematological
malignancies). The many different cancer entities in this study might be considered as a
weakness of this study, but at the same time, they could also be regarded as a strength of
this study representing a real world scenario of all cancer patients that were assessed with
24-h ECGs at our hospital during six consecutive years.
Most of the patients had an advanced disease stage (72%) with a high mortality
burden overall (median survival 15 months). Since the treating physicians had decided in
all cancer patients that a 24-h ECG was indicated based on clinical judgement, it has to be
acknowledged, that the patients in this cohort are a highly selected subgroup, and very
likely represent a high risk group of cancer patients for CV problems, even though patients
with a known LVEF <45% (6% of all cancer patients, LVEF was known in 197 of 277 cancer
patients [71%]) were excluded. Therefore, the results of this analysis may be affected by
the higher CV risk in our cancer patients and this may partly explain the high (17%) rates
of NSVTs of ≥3 beats during 24-h ECG recordings. In absolute terms, the subgroup of
lymphoma patients showed the lowest NSVT rates at 13% and lung cancer patients the
highest at 33%. As we have shown before, in unselected CV risk cancer patients, only
8% of patients showed NSVTs with ≥3 beats [15]. Therefore, the true burden of NSVT in
advanced cancer patients on average is most likely somewhere between 8–17%.
In this study we only analysed 24-h ECGs. None of our patients had longer ECG
recordings, e.g., for 7–10 days. It has been shown before, that the median change of PVCs
per day during 14-day ECG recordings is about 10% (IQR 5–15%) [18]—underlining the
importance of longer ECG recordings. At the same time, ECG recordings in general are
still rare in cancer patients in Germany. Future studies should focus on this.
We could not assess cause of death in any detail for all patients. Unfortunately, it is
notoriously difficult to ascertain the cause of death in cancer patients. The main reason
for this is because cancer patients often die at home or in hospices. Many cancer patients
and families do not want an autopsy to be performed after death, since it would be of no
benefit to them or the patient. Nonetheless, other much larger studies have found that,
irrespective of the time after cancer diagnosis, 20–30% of cancer patients die due to CV
disease [2,19,20], demonstrating that it is important to find new CV predictors of death in
cancer patients.
We have previously shown that chemotherapy naïve cancer patients demonstrate
mildly reduced LVEF [21]. Additionally, we have found that advanced cancer patients,
irrespective of their prior treatment and other concomitant factors, on average have an
elevated resting heart rate and that these cancer patients with heart rates ≥75 bpm have an
increased mortality [5]. Subsequently, we have demonstrated in a large prospective cohort
of 548 cancer patients that even in treatment naïve patients, an elevated resting heart rate is
independently associated with increased mortality. We recently published the hypothesis
that advanced cancer patients develop a new form of degenerative cardiomyopathy that
was termed “cardiac wasting-associated cardiomyopathy” [22,23]. We think that it is
caused by the many different factors that influence the function of the heart, including
neurohormones, onco-metabolites, cytokines, oxidative and metabolic stress, hypoxia,
fluid overload, chemo-, immune, and radiotherapy [21–24]. Together, all these factors can
lead to cardiomyocyte dysfunction, apoptosis, fibrosis, ventricular remodeling, cardiac
wasting, and even arrhythmias [22,23]. Most of the data underlining this hypothesis
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came from preclinical studies in animals. For example, Karlstaedt et al. demonstrated
that the oncometabolite d-2-hydroxyglutarate impairs the contractile function of hearts in
mice [25]. In rodents with colon adenocarcinoma, it was found that fractional shortening
of the hearts was significantly reduced compared to animals without cancer, and electron
microscopy identified a disrupted myocardial ultrastructure with increased fibrosis in these
animals [26]. In a mouse model with Lewis lung cell carcinoma, cancer development was
associated with cardiac remodelling and disturbance of the electrical conduction in the
heart (reduced axon length and less dense core vesicles in the axons) [27]. In humans, very
few reports have examined this question. Nonetheless, a detailed autopsy study, looking at
177 autopsies of cancer patients, found that those patients with cachexia before death had
significantly lower heart weight (19% lower heart weight) [28].
5. Conclusions
In conclusion, we found that cancer patients with primarily advanced disease de-
velop an increased vulnerability of the heart leading to ventricular arrhythmias, which are
associated with increased mortality. Retrospective studies show higher frequencies of ar-
rhythmias in cancer compared to prospective studies. We hypothesize that anti-arrhythmic
therapies for cancer patients may help in selected clinical scenarios and should perhaps be
tested in future trials.
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